Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs-Reference-Cited by-同舟云学术

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Published:2019-02-09 Issue:6 Volume:42 Page:751-768
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Ghosh Subrata,Gensler Lianne S.,Yang Zijiang,Gasink Chris,Chakravarty Soumya D.,Farahi Kamyar,Ramachandran Paraneedharan,Ott Elyssa,Strober Bruce E.

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/article/10.1007/s40264-019-00797-3/fulltext.html

Reference33 articles.

1. Kaushik SB, Lebwohl MG. CME part I psoriasis: which therapy for which patient. Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.06.057 (Epub 11 Jul 2018).

2. Kaushik SB, Lebwohl MG. CME part II psoriasis: which therapy for which patient. Focus on special populations and chronic infections. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.06.056 (Epub 11 Jul 2018).

3. Janssen Biotech, Inc. STELARA® (ustekinumab). Highlights of prescribing information. http://www.stelarahcp.com/pdf/PrescribingInformation.pdf . Accessed 30 May 2017.

4. Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab. A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–45.

5. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74.

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target;Expert Opinion on Biological Therapy;2024-09-08

2. Biologics for Psoriasis;Dermatologic Clinics;2024-07

3. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis;Annals of the Rheumatic Diseases;2024-03-19

4. Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study;Journal of Clinical Medicine;2024-02-14

5. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis;Journal of Crohn's and Colitis;2024-02-04